Neurology
Weber is new CMO at Sensorion
October 28, 2026Ear Nose & throat, Genetic disorders, Neurology, hearing loss
Otologist and neurotologist Dr. Peter Weber has been appointed Chief Medical Officer of biotech Sensorion. The company, which develops novel …
SMC accepts atogepant for acute migraine treatment in Scotland
October 22, 2026Neurology, SMC, clinical trial, migraine
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the acute treatment of migraine with …
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
October 15, 2026Diagnostics, Haematology, Neurological Diseases, Neurology, Parkinson's disease, blood testing, sleep disorder
Researchers at King Abdullah University of Science and Technology (KAUST) and the University of Oxford have developed a blood-based electronic …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
October 13, 2026Cardiology, Neurology, Parkinson's disease, Vaccine, clinical trial
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, an intradermal therapeutic vaccine targeting …
Bio-Techne opens GMP small-molecule manufacturing facility in Bristol
October 13, 2026Cardiology, Cleanroom, Diabetes, Haematology, Neurology, Rare Diseases, cell therapies, manufacturing and production, small molecules
Bio-Techne has opened a new facility in Bristol manufacturing Good Manufacturing Practice (GMP)-grade small molecules for cell therapy developers. The …
UK immunoglobulin supply faces growing pressure, report warns
October 12, 2026Manufacturing and Production Critical supplies, Immunology, NHS Blood and Transplant, Neurology, procurement
The UK may face increasing pressure to secure long-term supplies of immunoglobulin (Ig), with rising demand and heavy reliance on …
FDA signals support for development of psychedelic therapies in mental healthmental health
April 28, 2026Neurology, mental health
The US Food and Drug Administration (FDA) has announced a series of measures aimed at supporting the development of psychedelic-based …
Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals
February 17, 2026Manufacturing and Production Gedeon Richter UK, Neurology
Gedeon Richter UK has announced its acquisition of full marketing and distribution rights to Reagila (cariprazine), a schizophrenia treatment, from …
HonorHealth Research Institute announces first patient dosed with new stroke treatment
February 2, 2026Research and Development HonorHealth Research Institute, Neurology, ischemic stroke
HonorHealth Research Institute, a research institution collaborating with a wide range of experts to produce new treatments and devices, has …
Five Facts about spinal muscular atrophy
January 28, 2026Medical Communications Five Facts, Neurology, early diagnosis, five types, gene therapy, muscle weakness, spinal muscular atrophy
1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons in the spinal cord.1 Its …
Spike in searches relating to spinal muscular atrophy following Jesy Nelson disclosure
January 19, 2026Medical Education Neurology, spinal muscular atrophy
New research from the Centre for Surgery has shown a significant rise in Google searches relating to spinal muscular atrophy …
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
January 19, 2026Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …
Teva’s Ajovy significantly reduces migraine in children and adolescents
January 12, 2026Research and Development Neurology, Teva, ajovy, migraine
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine …
EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy
December 10, 2025Research and Development EpilepsyGTx, Neurology, epilepsy
EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
December 8, 2025Research and Development Neurology, UCB, epilepsy
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
